We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Partnership Focuses on Neurodegenerative Diseases.
- Authors
Rubin, Rita
- Abstract
The 2 federal agencies are partnering with the Critical Path Institute (C-PATH) - an independent nonprofit, public-private partnership created in 2005 under the auspices of the FDA's Critical Path Initiative program - on the Critical Path for Rare Neurodegenerative Diseases. The partnership is a key component of the FDA's Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis, which was announced in June. News From the Food and Drug Administration The FDA and the National Institutes of Health (NIH) have launched a public-private partnership to advance the understanding of and accelerate the development of treatments for rare neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
- Subjects
TREATMENT of neurodegeneration
- Publication
JAMA: Journal of the American Medical Association, 2022, Vol 328, Issue 15, p1492
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2022.15479